Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07093580 · ClinicalTrials.gov registry record · Phase 1
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
A Phase 1 study of Healthy Participants, sponsored by Shionogi.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
- 2
- Study locations
NCT07093580: Recruiting Phase 1 study of Healthy Participants, sponsored by Shionogi.
NCT07093580 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by Shionogi. The registered enrollment target is 98 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (51% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07093580, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by Shionogi.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG S-892216-LAI
Study Locations (2)
Kansas
- ICON Clinical Research: Lenexa - Lenexa
Utah
- ICON Clinical Research: Salt Lake City - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2025-07-29 |
| Est. Completion | 2027-05-26 |
| Phase | Phase 1 |
What NCT07093580 shows while recruiting
NCT07093580 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (51% higher).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07093580 reports a single indexed study location in Kansas, Utah.
Frequently Asked Questions
What is clinical trial NCT07093580 about?
NCT07093580 is a clinical study titled "Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants". The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
What is the current status of trial NCT07093580?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2025-07-29. Estimated completion is 2027-05-26.
What conditions does trial NCT07093580 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07093580?
The interventions under investigation include: Placebo (DRUG), S-892216-LAI (DRUG).
Who is sponsoring clinical trial NCT07093580?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07093580 being conducted?
This trial has 2 study locations across Kansas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07093580's enrollment target sits among peer trials
98 25th of 119 higher than 95 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI